EVP

Consolidated Water to Attend the 36th Annual ROTH Conference, March 17-19, 2024

Retrieved on: 
Thursday, February 22, 2024

Past conferences have attracted more than 5,000 participants, including institutional investors, family offices, high-net-worth investors, and equity analysts.

Key Points: 
  • Past conferences have attracted more than 5,000 participants, including institutional investors, family offices, high-net-worth investors, and equity analysts.
  • On March 18-19, Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with analysts and investors.
  • To schedule a one-on-one meeting with Consolidated Water, please contact your ROTH representative.
  • For questions or further information about Consolidated Water, please contact Ron Both of CMA at (949) 432-7557, or submit your request here .

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, February 21, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.

Key Points: 
  • Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
    Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595
    BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
  • Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company’s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions.
  • Dr. Germa added, “I am thrilled to be joining Ikena at a time when it is primed for clinical inflection across the pipeline.
  • Dr. Santillana’s leadership was integral to bringing our programs into the clinic, and we wish him well in his future endeavors.”

Vevo Partners With PubMatic to Expand Programmatic Buying Across its Global CTV Network

Retrieved on: 
Wednesday, February 21, 2024

The collaboration will allow for an accelerated phase of programmatic CTV growth for Vevo, allowing advertisers to drive scaled reach across its premium library.

Key Points: 
  • The collaboration will allow for an accelerated phase of programmatic CTV growth for Vevo, allowing advertisers to drive scaled reach across its premium library.
  • Vevo’s global network spans more than 800,000 videos, boasting a total monthly average of 25 billion views.
  • Partnering with PubMatic will offer unprecedented access to Vevo’s expansive high-quality CTV inventory for media buyers globally.
  • PubMatic's Nicole Scaglione, Global VP for CTV/OTT and Video says: “This collaboration marks a major milestone on multiple fronts.

Crown Castle Reiterates Actions Underway to Enhance and Unlock Shareholder Value

Retrieved on: 
Tuesday, February 20, 2024

HOUSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today confirmed that Boots Capital Management, LLC (“Boots Capital”), which is led by Ted Miller, has nominated four candidates to stand for election to Crown Castle’s Board of Directors (“Board”) at the Company’s 2024 Annual Meeting of Stockholders. Mr. Miller is a co-founder of Crown Castle and resigned as CEO and a Director of the Company in 2001 and 2002, respectively.

Key Points: 
  • Mr. Miller is a co-founder of Crown Castle and resigned as CEO and a Director of the Company in 2001 and 2002, respectively.
  • The Crown Castle Board and management team are confident in the actions the Company is taking to remain well positioned for long term success and shareholder value creation.
  • The Crown Castle Board and management team value constructive dialogue with shareholders and regularly engage with an open mind to better understand their perspectives on the Company’s strategy, performance and business objectives.
  • While we recognize Mr. Miller’s contributions to the formation of Crown Castle more than twenty years ago, Boots Capital’s nominees do not possess the relevant expertise and experience to successfully oversee Crown Castle’s strategy.

US Department of Health and Human Services Selects Inmar Intelligence for a 5-year Contract to Deliver Pharmaceutical Supply Chain Solutions

Retrieved on: 
Tuesday, February 20, 2024

Winston-Salem, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Inmar Intelligence , a leading provider of data-driven healthcare technology solutions, today announced it has secured a contract with the US Department of Health and Human Services (HHS) to provide pharmaceutical supply chain solutions across the country.

Key Points: 
  • Winston-Salem, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Inmar Intelligence , a leading provider of data-driven healthcare technology solutions, today announced it has secured a contract with the US Department of Health and Human Services (HHS) to provide pharmaceutical supply chain solutions across the country.
  • With pharmaceutical supply chain management needs at an all-time high, this contract represents a timely opportunity for Inmar to deploy its tech-enabled pharmaceutical services nationwide.
  • Leveraging decades of expertise providing tech-forward solutions, Inmar will support HHS in their mission to protect public health and provide essential human services.
  • With health emergencies on the rise, Inmar reaffirms its dedication to helping safeguard public health services now and into the future.

At MWC, InterDigital to Showcase Innovation Empowering Connected Experiences ‘At Work, At Rest, and At Play’

Retrieved on: 
Monday, February 19, 2024

“InterDigital innovation creates value through the tools we create and through the experiences they enable,” said Rajesh Pankaj, EVP and CTO at InterDigital.

Key Points: 
  • “InterDigital innovation creates value through the tools we create and through the experiences they enable,” said Rajesh Pankaj, EVP and CTO at InterDigital.
  • InterDigital is a long-time contributor to MPEG Immersive Standards, including Scene Description, V3C codecs alongside partner Philips, and newer haptics codecs to enable seamless, immersive experiences.
  • Elsewhere at MWC, InterDigital will lead stage presentations and showcase at partner booths to further amplify the impact of our research and innovation.
  • At the Keysight booth located at Hall 5 Stand 5E12, InterDigital and Keysight will together showcase a 144 GHz testbed utilizing an AI-enabled air interface.

LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 8, 2024

LEO Pharma A/S, a global leader in medical dermatology, today unveiled new data analyzing the long-term therapeutic response of treatment with Adbry® (tralokinumab-ldrm) in adults (18 years and above) with moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today unveiled new data analyzing the long-term therapeutic response of treatment with Adbry® (tralokinumab-ldrm) in adults (18 years and above) with moderate-to-severe atopic dermatitis (AD).
  • The findings are being shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego, California.1
    The results are part of a wide-ranging data program from LEO Pharma at AAD, with eight abstracts accepted in total for the meeting, showcasing an ongoing commitment to advancing the standard of research in medical dermatology.
  • “The data presented for Adbry at AAD further builds upon an established, wide-ranging collection of clinical evidence that aims to improve the support for those living with moderate-to-severe AD,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.
  • “This new analysis demonstrates the benefits of the long-term use of Adbry for adults who live with this chronic condition.”

Estrella Media to Present the Iconic Paquita la del Barrio at Its Los Angeles and Houston Cinco de Mayo Concert Events

Retrieved on: 
Friday, March 8, 2024

Estrella Media, the transformative Spanish‑language media company serving the valuable multi-platform Latino audience in the U.S., announced that the iconic Paquita la del Barrio will headline its annual Cinco de Mayo events in Los Angeles and Houston.

Key Points: 
  • Estrella Media, the transformative Spanish‑language media company serving the valuable multi-platform Latino audience in the U.S., announced that the iconic Paquita la del Barrio will headline its annual Cinco de Mayo events in Los Angeles and Houston.
  • Almost 50,000 people attended the 2023 events in Los Angeles and Houston.
  • “We are proud to celebrate 50 years of stunning artistry and music with ‘La Reina de las Mujeres,’” said Eddie Leon, EVP of Radio Programming and Events, Estrella Media.
  • It’s a beautiful way to lead into Mother’s Day by celebrating the mother of Mexican music, Paquita la del Barrio.”
    Paquita la del Barrio is an iconic GRAMMY-winning artist, songwriter, and actress.

Fifth Annual MedExecWomen Conference in April to Discuss This Year’s Top Opportunities in Medtech

Retrieved on: 
Thursday, March 7, 2024

McEvoy will share eye-opening insights from nearly three decades of experience creating transformational change in healthcare.

Key Points: 
  • McEvoy will share eye-opening insights from nearly three decades of experience creating transformational change in healthcare.
  • The one-day conference also features an agenda of workshops and panels and speakers that span some of this year’s top challenges and opportunities related to medtech innovation, including:
    What do Leading Physicians Think are the Most Innovative Trends in Medtech?
  • “Women in life sciences don’t often get mentors, education, and a network,” said Maria Shepherd , co-founder of MedExecWomen and president of Medi-Vantage.
  • “This conference and community establish this network and bring together a powerhouse group of women in medtech for a truly unique opportunity to connect with one another and discuss some of the most pressing changes and opportunities in medtech each year.”
    Save your spot for this must-attend event for women in medtech — register online today.

Insite AI Launches Shopper AI™: Delivering the ‘Why’ Behind Shopper Behavior Trends, Powered by Predictive Analytics and Generative AI

Retrieved on: 
Thursday, March 7, 2024

Shopper AI from Insite AI harmonizes a brand’s disparate sources of shopper data, mines for insights and provides an immediate AI-powered shortcut to actionable recommendations.

Key Points: 
  • Shopper AI from Insite AI harmonizes a brand’s disparate sources of shopper data, mines for insights and provides an immediate AI-powered shortcut to actionable recommendations.
  • Insite AI can help brands make this data actionable through Shopper AI.
  • Shopper AI goes beyond the data to review certain market conditions, price elasticities, demand transference, shifts in shopper behavior and more.
  • Shopper AI goes much further, leveraging AI to explain what the data means and suggest a plan of action,” said Kristine Joji, EVP, strategy consulting, Insite AI.